Diabetologia (2007) 50:2611–2613
DOI 10.1007/s00125-007-0845-3

ERRATUM

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus

A. Hiukka · E. Leinonen · M. Jauhiainen · J. Sundvall · C. Ehnholm · A. C. Keech · M. R. Taskinen

Published online: 10 October 2007

An incorrect conversion factor was used by the authors resulting in values given in g/l being ten times higher than they should have been. The corrected sections of Tables 1, 2, 3, 4 are reproduced below.

In addition there are two text corrections:

The last paragraph of the Abstract should have read:

Conclusions/interpretation Fenofibrate markedly reduced large VLDL particles and produced a clear shift in HDL subspecies towards smaller particles. The HDL3-C increase in conjunction with unchanged apoA-I levels is a dilemma with regard to cardiovascular disease.

The last sentence of the subsection on 'Impact of homocysteine levels on HDL' in the Results should have read:

In patients with low homocysteine levels (n=42), HDL-C and apoA-I levels were slightly increased by fenofibrate (Δ=0.05 mmol/l for HDL-C and Δ=0.034 g/l for apoA-I), whereas in patients with high homocysteine levels (n=42) HDL-C and apoA-I levels decreased (Δ=−0.04 mmol/l for HDL-C and Δ=−0.014 g/l for apoA-I) (p=0.028 for both the differences in ΔHDL-C and ΔapoA-I between the low and high homocysteine groups).

The online version of the original article can be found at: http://dx.doi.org/10.1007/s00125-007-0751-8.

A. Hiukka · E. Leinonen · M. R. Taskinen (✉)
Department of Medicine, Division of Cardiology,
Helsinki University Hospital and Biomedicum,
Haartmaninkatu 8,
00290 Helsinki, Finland
e-mail: Marja-Riitta.Taskinen@helsinki.fi

M. Jauhiainen · C. Ehnholm
Department of Molecular Medicine,
National Public Health Institute and Biomedicum,
Helsinki, Finland

J. Sundvall
Department of Health and Functional Capacity,
National Public Health Institute,
Helsinki, Finland

A. C. Keech
NHMRC Clinical Trials Centre, University of Sydney,
Sydney, NSW, Australia

Table 1 Basic lipid panel and lipid transfer protein activities before and during Fenofibrate treatment

	Baseline	Fifth year		*p* value
			Difference of change between the groups	
apoB (g/l)				
Placebo	0.96 (0.82–1.07)	1.00 (0.89–1.17)		
Fenofibrate	1.00 (0.91–1.12)	0.84 (0.70–0.98)	−24.7 (−18.4, −31.0)	<0.001

Table 2 Triacylglycerol, cholesterol and particle mass concentration of VLDL 1, VLDL 2 and IDL in type 2 diabetic patients

	Baseline	Second year		Fifth year		*p* value
			Difference of change between the groups		Difference of change between the groups	
VLDL1 particle mass (g/l)						
Placebo	0.88 (0.50–1.44)	0.85 (0.51–1.20)	−39.4 (−25.6, −53.6)	0.81 (0.51–1.26)	−43.5 (−29.5, −59.4)	<0.001
Fenofibrate	0.85 (0.49–1.42)	0.47 (0.25–0.73)		0.38 (0.22–0.85)		
VLDL2 particle mass (g/l)						
Placebo	0.60 (0.42–0.78)	0.60 (0.41–0.80)	−32.1 (−19.2, −44.8)	0.54 (0.42–0.80)	−32.5 (−20.0, −45.3)	<0.001
Fenofibrate	0.58 (0.39–0.78)	0.36 (0.24–0.52)		0.38 (0.23–0.60)		
IDL particle mass (g/l)						
Placebo	0.39 (0.30–0.50)	0.39 (0.30–0.46)	−5.7 (2.6, −14.5)	0.40 (0.32–0.47)	−12.0 (−2.0, −21.5)	0.019
Fenofibrate	0.38 (0.30–0.49)	0.33 (0.26–0.43)		0.32 (0.25–0.46)		

Table 3 Cholesterol concentration, particle mass of HDL2 and HDL3, and concentrations of apolipoproteins and apoA-containing lipoproteins in type 2 diabetic patients

	Baseline	Second year		Fifth year		*p* value
			Difference of change between the groups		Difference of change between the groups	
HDL2 Particle mass (g/l)						
Placebo	0.89 (0.72–1.20)	0.89 (0.71–1.22)	−20.0 (−12.5, −28.0)	0.97 (0.71–1.41)	−23.1 (−13.6, −32.2)	<0.001
Fenofibrate	0.95 (0.72–1.29)	0.73 (0.55–0.96)		0.76 (0.61–1.02)		
HDL3 Particle mass (g/l)						
Placebo	2.13 (1.93–2.35)	2.32 (2.16–2.58)	7.7 (2.8, 12.8)	2.41 (2.26–2.65)	12.5 (7.2, 17.9)	<0.001
Fenofibrate	2.14 (1.92–2.28)	2.50 (2.24–2.71)		2.69 (2.44–2.94)		
apoA-I (g/l)						
Placebo	1.34 (1.21–1.51)	1.32 (1.21–1.48)	−0.7 (−4.2, 2.8)	1.34 (1.23–1.51)	−0.5 (−3.9, 3.7)	NS
Fenofibrate	1.36 (1.25–1.45)	1.32 (1.21–1.46)		1.34 (1.25–1.50)		
apoA-II (g/l)						
Placebo	0.34 (0.31–0.37)	0.34 (0.31–0.39)	22.9 (18.2, 28.1)	0.31 (0.27–0.37)	26.9 (19.6, 34.4)	<0.001
Fenofibrate	0.33 (0.30–0.37)	0.40 (0.37–0.46)		0.42 (0.35–0.48)		
LpA-I (g/l)						
Placebo	0.48 (0.41–0.61)	0.46 (0.37–0.59)	−20.4 (−13.4, −27.5)	0.48 (0.39–0.65)	−21.1 (−12.7, −30.0)	<0.001
Fenofibrate	0.49 (0.41–0.59)	0.35 (0.30–0.42)		0.39 (0.31–0.45)		
LpAI-AII (g/l)						
Placebo	0.83 (0.75–0.90)	0.86 (0.78–0.95)	10.6 (5.5, 16.0)	0.83 (0.77–0.96)	11.5 (5.3, 17.3)	<0.001
Fenofibrate	0.83 (0.77–0.92)	0.96 (0.89–1.06)		0.97 (0.88–1.07)		

Table 4 The baseline HDL panel in the groups of low and high homocysteine levels

	Lowest quartile (n=56)	Highest quartile (n=60)	p value
apoA-I (g/l)	1.37 (1.21–1.55)	1.29 (1.19–1.43)	0.131
apoA-II (g/l)	0.34 (0.30–0.38)	0.32 (0.31–0.36)	0.040
LpA-I (g/l)	0.51 (0.41–0.65)	0.48 (0.41–0.61)	0.904
LpAI-AII (g/l)	0.85 (0.79–0.93)	0.81 (0.74–0.87)	0.017